monoclonal antibody cd20
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 1999 (NCT00003874)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20INHIBITOR
MS4A1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- monoclonal antibody cd20
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05258136 | N/A | Jun 1, 2021 | Capital Medical University |
| NCT00003874 | Phase 1/Phase 2 (Phase 2) | Feb 1, 1999 | National Cancer Institute (NCI), Rutgers University, University of Washington |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 1999 |
| Rutgers University | Academic/Hospital | 1 | 0 | 1 | 1999 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 1999 |
4 organizations
Page 1 / 1